TrialsgrambetaRCTs are beautiful

HOKUSAI-VTE

2013

Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism

In 8,240 patients with acute venous thromboembolism after initial heparin, once-daily edoxaban was non-inferior for recurrent symptomatic venous thromboembolism and caused less clinically relevant bleeding than warfarin.

Result

Efficacy: Recurrent symptomatic venous thromboembolismHR 0.89 (95% CI 0.70-1.13) · P < 0.001

Safety: Major or clinically relevant bleedingHR 0.81 (95% CI 0.71-0.94) · P = 0.004

Below 1 favours once-daily edoxaban, above 1 favours warfarin.

Event rates Once-daily edoxaban 3.2% vs warfarin 3.5% (recurrent symptomatic venous thromboembolism)

Also reported: In PE with right-ventricular dysfunction, recurrence 3.3 % vs 6.2 % (HR 0.52).

Original publication
Subtopic
Venous thromboembolism
Design
Double-blind, double-dummy non-inferiority RCT
Relevance
Important: one of several pillars.
Source
The Hokusai-VTE Investigators. N Engl J Med. 2013;369(15):1406-1415.doi 10.1056/NEJMoa1306638

Discussion & critique

A heparin lead-in is mandatory, so this is not a single-drug regimen. Its double-blind design, high-quality warfarin comparator and the pre-specified right-ventricular-dysfunction subgroup make it the strongest DOAC evidence in the sicker end of the PE spectrum.